Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Xeris Biopharma (NASDAQ:XERS) issued its quarterly earnings data on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03, reports. The business had revenue of $85.81 million for the quarter, compared to analysts’ expectations of $86.00 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Financial self-sustainability achieved — Xeris reported full-year net income and ~$59.4M adjusted EBITDA in 2025 and guided 2026 revenue of $375–$390M while expecting to remain adjusted EBITDA positive.
• Recorlev is the primary growth engine, ending 2025 at ~700 patients (nearly double year‑over‑year) with FY revenue of $139.3M, and the company nearly doubled its commercial team in January to accelerate adoption with impacts expected notably in H2 2026.
• Xeris filed a patent infringement lawsuit against two ANDA filers to defend Recorlev and points to four Orange Book‑listed patents through March 2040 and orphan exclusivity to end of 2028, but litigation timelines are uncertain and could create a multi‑year overhang.
• The pipeline priority XP‑8121 (once‑weekly subcutaneous levothyroxine) is planned to start Phase 3 in H2 2026, targets an estimated 3–5M patients with absorption issues, and is modeled for potential peak sales of $1–$3B, with R&D budget to increase by about $25M to support the program.
• The commercial portfolio is durable — Gvoke and Keveyis delivered steady contributions, gross margin improved to ~85% for 2025 (87% in Q4), and management expects further margin improvement and continued operating leverage despite planned SG&A investments (~$45M) to scale Recorlev.

Xeris Biopharma Price Performance

NASDAQ:XERS traded down $0.10 during trading hours on Monday, hitting $6.02. 5,043,566 shares of the company were exchanged, compared to its average volume of 2,062,871. Xeris Biopharma has a 52-week low of $3.59 and a 52-week high of $10.08. The stock has a market capitalization of $998.86 million, a price-to-earnings ratio of -60.19 and a beta of 0.52. The company’s 50 day moving average price is $7.23 and its 200-day moving average price is $7.64.

Insiders Place Their Bets

In other news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the sale, the insider directly owned 1,308,103 shares in the company, valued at approximately $9,719,205.29. The trade was a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the sale, the director directly owned 142,500 shares in the company, valued at $1,010,325. This trade represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 223,641 shares of company stock valued at $1,628,285. Corporate insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of XERS. Kestra Advisory Services LLC acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd increased its holdings in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the last quarter. Truvestments Capital LLC raised its position in Xeris Biopharma by 96.1% during the 4th quarter. Truvestments Capital LLC now owns 8,118 shares of the company’s stock worth $64,000 after buying an additional 3,979 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Xeris Biopharma during the 4th quarter valued at approximately $67,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results beat on EPS and management raised FY‑2026 revenue guidance — Xeris reported $0.06 EPS vs. $0.03 consensus and issued revenue guidance of $375.0M–$390.0M (above the $370.3M consensus), a constructive top‑line outlook that can support valuation and growth expectations. Press Release
• Positive Sentiment: HC Wainwright reaffirmed a Buy and set a $10 price target — analyst backing and a mid‑double‑digit upside target (about 66% from current levels) provide a bullish catalyst if sentiment improves. HC Wainwright Reaffirmation
• Neutral Sentiment: Conference call / transcripts available — management commentary and the Q&A will be key for clarity on margin drivers, growth cadence, and timing of any product/lifecycle initiatives. Earnings Call Transcript
• Neutral Sentiment: Press coverage and analyst notes summarize the results — most outlets note the EPS beat but highlight that reported revenue of $85.81M was just shy of the $86.0M estimate (a mixed signal). Zacks Coverage
• Negative Sentiment: Recurlev/Recorlev exclusivity and valuation risk — recent coverage highlights Xeris’ efforts to defend Recorlev exclusivity; litigation/regulatory outcomes are uncertain and could materially affect future revenue. Yahoo Valuation / Exclusivity Article
• Negative Sentiment: Guidance omitted EPS detail and revenue miss vs. quarterly estimate — while revenue guidance was raised, management didn’t provide clear EPS guidance in the release and quarter revenue was a touch below expectations, leaving short‑term profitability visibility limited. No link

Analysts Set New Price Targets

A number of research analysts have recently issued reports on XERS shares. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Piper Sandler raised their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Oppenheimer reiterated an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday. Finally, Barclays started coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.08.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.